








































Telomeres are protective caps at chromosome ends that 
consist of G rich repeats and associated proteins [1, 2]. 
Their major functions are to buffer replication 
associated shortening, and to protect chromosome ends 
from being processed as double stranded breaks by the 
cellular repair machinery. Telomeres can lose their 
protective function by excessive erosion of the 
telomeric DNA tracts, as demonstrated in mouse models 
where the RNA subunit or the catalytic subunit of 
telomerase have been subjected to targeted deletion [3, 
4]. When telomeres become critically short they fail to 
form a protective structure  and are recognized as  DNA  
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Abstract: The  telomeric  repeat  binding  factor  2  (TRF2)  plays  a  central  role  in  the  protection  of  chromosome  ends  by
inhibiting  telomeres  from  initiating  a DNA  damage  cascade.  TRF2  overexpression has  been  suggested  to  induce  tumor
development  in  the  mouse,  and  TRF2  levels  have  been  found  increased  in  human  tumors.  Here  we  tested  whether
moderate expression of TRF2 in the hematopoietic system leads to cancer development in the mouse. TRF2 and a GFP‐TRF2









damage, leading to cell cycle arrest, repair, or cell death 
[1, 5]. Repair of critically short telomeres, mostly 
accomplished by the non-homologous end joining  
(NHEJ) machinery, results in covalent fusion of 
chromosome ends [6]. When a cell passes through 
mitosis with fused chromosomes they break randomly, 
leading to unequal distribution of DNA to the daughter 
cells, and hence to genome instability. It has been 
shown extensively that telomere dysfunction results in 
unstable chromosomes, and can therefore lead to 
neoplastic transformation [1, 5, 7, 8]. 
 
The core complex of telomere associated proteins is 
termed shelterin, and consists of TRF1, TRF2, RAP1, 
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TIN2, TPP1 and POT1, and plays a crucial role in 
telomere protection and the regulation of telomere 
length homeostasis [2]. Disruption of the complex leads 
to telomere dysfunction, often without extensive loss of 
telomeric double stranded DNA. It has been well 
established that many levels of protection exist and that 
they interact to inhibit the DNA damage machinery at 
natural chromosome ends. It is challenging to assign 
individual roles to the proteins in the complex, since 
disruption of any component might cause 
destabilization of shelterin. For example, deletion of 
TRF1 or TIN2 in mice causes embryonic lethality 
independent of telomerase dependent telomere length 
regulation [9, 10]. Since TIN2 interacts with both TRF1 
and TRF2 [11-13], it is unclear at this point what the 
exact pathway to lethality is. Similarly, suppression of 
POT1 led to partial loss of the telomeric 3’ single 
stranded overhang, and a transient detection of 
telomeres by the DNA damage machinery [14]. The 
protective effects of POT1 are dependent on its 
interactions with TPP1 [15], again demonstrating the 
interdependence of the members of shelterin. POT1 also 
protect telomeres by preventing activation of the ATR 
dependent DNA damage response machinery [16]. 
Inhibition of TRF2 by a dominant negative allele or by 
targeted deletion leads to extensive loss of the single 
stranded overhang and to dependent chromosome fusion 
by NHEJ [6, 17-20]. TRF2 also represses the ATM 
dependent DNA damage response [16], potentially by 
directly interacting with the kinase [21]. 
 
Relatively little is known about the role the shelterin 
components play in tumorigenesis. TRF1, TRF2 and 
TIN2 have been found up-regulated occasionally during 
in gastric carcinomas and during hepatocarcinogenesis 
[22, 23]. Mutations in TIN2 have been demonstrated to 
lead to abnormally short telomeres, and to be associated 
with dyskeratosis congenita and ataxia-pancytopenia, 
diseases associated with an increased cancer disposition 
[24-26]. 
 
Despite the fact that shelterin components interact with 
proteins involved in many repair processes [2, 27-30], 
no general trend for de-regulation in tumors has been 
observed. In an effort to study TRF2 overexpression in 
a mammalian organism mTRF2 has been overexpressed 
under the K5 promoter in basal and stem cells of the 
epidermis [31, 32]. This led to XPF dependent telomere 
loss and increased skin cancer levels in the animals 
[31], a phenotype that was accelerated by telomerase 
abrogation [32]. 
TRF2 has also been demonstrated to directly interact 
with ATM, and overexpression of TRF2 can partially 
prevent ATM phosphorylation and the activation of the 
ATM dependent DNA damage response [21, 33]. Based 
on this finding we set out to test whether modest TRF2 
overexpression in the murine hematopoietic system 
leads to a suppression of the DNA damage response and 
to lymphoma development, as demonstrated for mice 
lacking ATM [34]. Here we show that TRF2 and GFP-
TRF2 can be overexpressed in the hematopoietic system 
of C57BL/6J mice, and that the transgenic TRF2 
localizes to telomeres. Approximately 15% of animals 
that were secondary recipients of TRF2 overexpressing 
hematopoietic precursors developed T cell lymphomas. 
Although lymphoma incident was elevated in this 
cohort, most mice did not develop cancer during their 
life-span, suggesting that TRF2 is not a dominant 
oncogene in this system. 
 
RESULTS AND DISCUSSION 
 
Overexpressed mTRF2 and GFP-mTRF2 localize to 
telomeres 
 
Wild type mouse TRF2 (mTRF2), a fusion of GFP and 
mTRF2, as well as a GFP control were introduced into 
lentiviral constructs under the control of the CAG 
promoter (Figure 1A), and the constructs were 
transfected into murine 3T3 fibroblasts. Indirect 
immunofluorescence of control 3T3 cells with 
antibodies against mTRF1 and mTRF2 revealed 
telomeric co-localization of the two proteins (Figure 1B, 
upper panel). The GFP-mTRF2 fusion protein also co-
localized with endogenous mTRF1, demonstrating that 
the fusion protein localizes to telomeres (Figure 1B, 
middle panel). Similarly, overexpressed mTRF2 
localized to telomeres (Figure 1B, lower panel), as 
detected by immunofluorescence with antibodies 
against mTRF1 and mTRF2. To test whether mTRF2 
was also expressed and localizes to telomeres in 
hematopoietic precursors, high titer lentiviruses were 
generated, and a liquid culture of CD45.1 donor bone 
marrow was infected with the lentiviruses, and 
expression and localization was tested by immuno-
fluorescence. Co-localization of mTRF1 and GFP-
mTRF2 demonstrated the telomeric localization of the 
fusion protein (Figure 1C), as well as the wild type 
TRF2 allele (data not shown). The cell lines expressing 
the transgenes did not display altered growth rates or 
cell death (data not shown), suggesting that the 
expressed TRF2 alleles do not interfere with telomere 
protection. 
 
TRF2 constructs integrate and express in bone 
marrow and spleen of transgenic C57BL/6J mice 
 
Donor bone marrow was infected in two independent 
sets of experiments, where either GFP positive donor 
cells or CD45.1  expressing  donor  cells were used for  
  




















































infection. This approach allows identification of the 
transplanted cells in the recipient bone marrow by 
FACS analysis later. In the first set GFP positive donor 
bone marrow was infected with lentiviruses expressing 
wild type mTRF2 and then re-introduced into the tail 
veins of 13 lethally irradiated C57BL/6J donor mice. 
Alternatively, CD45.1 bone marrow was infected with 
GFP-mTRF2 expressing lentiviruses, and was injected 
into the tail veins of 19 lethally irradiated C57BL/6J 
donor mice (Figure 2A, left panel). 
 
In the second set only CD45.1 donor bone marrow was 
used, and 17 mice were generated that expressed a GFP 
control, 19 that received cells that expressed wild type 
mTRF2, and 17 that were transduced with cells 
expressing the GFP-mTRF2 fusion (Figure 2A, right 
panel). 
 
After recovery and repopulation of the bone marrow 
with donor cells, we tested the presence of the transgene 
in DNA isolated form whole blood of the recipient 
animals. Using a PCR based approach (Figure 2B) 
followed by southern analysis 26 mice of the first 
infection-set tested positive for the presence of the 
transgene in blood, as well as 15 animals of the second 
set. Mice transplanted with bone marrow that was 
infected with GFP control viruses did not give a signal 
in the PCR-southern analysis. In summary, we 
generated 41 animals that expressed mTRF2 or mTRF2-
GFP transgenes in their bone marrow. 
 
Transplantation of bone marrow from primary 
recipients into secondary C57BL/6J recipient mice 
 
To further promote tumor progression in recipient mice, 
we transplanted bone marrow from primary recipient 
mice that were successfully transduced with transgenic 
TRF2. Primary bone marrow from both primary sets 
was isolated four months post infection and transplanted 
into lethally irradiated C57BL/6J secondary recipients. 
A total of five secondary recipient populations were 
generated: two populations with a total of 26 animals 
received bone marrow expressing mTRF2, another two 
populations with a total of 28 animals received bone 
marrow expressing GFP-mTRF2. As negative control a 
population of 30 animals received bone marrow 
transduced with the GFP transgene. 
Figure 1. Lentiviral expression of mTRF2 and GFP‐mTRF2.
(A)  Schematic  of  transgene  constructs.  GFP,  mouse  TRF2
(mTRF2)  and  a GFP‐mTRF2  fusion were  cloned  into  a  lentiviral
vector system (35) under the control of a CAG promoter (38). (B)
Indirect  immunofluorescence of 3T3 cells. 3T3 control cells (top
panel),  3T3  cells  transfected  with  GFP‐mTRF2  and  cells
transfected  with  the  mTRF2  construct  were  stained  with
antibodies  against  mTRF1  or  mTRF2.  GFP  was  visualized  by
autofluorescence.  DNA  has  been  stained  with  DAPI,  and  the
merge of the red, green and blue channels has been provided on
the  right.  (C)  Indirect  immunofluorescence  of  CD45.1  donor
bone  marrow  cells.  Cells  were  infected  with  GFP‐mTRF2 
expressing  lentiviruses  and  GFP‐mTRF2  was  visualized  by  GFP




To test for functionality of the TRF2 alleles in the 
integrated cell populations we isolated bone marrow as 
well as splenocytes from secondary recipient animals. 
Immunofluorescent staining demonstrated clear co-
localization of GFP-TRF2 with TRF1 in bone marrow 
cells (Figure 2C, upper panel) and splenocytes (Figure 
2C, lower panel), suggesting telomeric localization and 
functionality. In summary, transgenic mTRF2 integrates 
into donor cells, which keep expressing the transgene 
after repopulating the bone marrow of lethally irradiated 
recipient animals. 
  


















































Development of T-cell lymphoma without TRF2 
overexpression 
 
A modest increase in the development of T-cell 
lymphoma was observed in secondary recipient mice 
that were transduced with TRF2 expressing cells within 
12-month post transplantations, as opposed to GFP 
control cells. 8 out of 54 mice (14.8%) that tested 
positive for mTRF2 transgenes succumbed to visible 
tumors within 52 weeks of transplantation, whereas 
none of the 30 control mice that carried the GFP 
transgene displayed visible tumors within the same 
timeframe. Tissue samples from a secondary recipient 
mouse suggested development of a large cell blastic T-
cell lymphoma (Figure 3A, lower two panels). Spleen, 
liver and thymus were infiltrated and the organ cells 
replaced by a diffuse monotonous neoplastic infiltrate 
composed of cells with large oval nuclei with a delicate 
chromatin pattern and spare cytoplasm. The cells had a 
high mitotic index, but also displayed the foci 
characteristic for apoptosis. The renal glomeruli 
displayed thickening of the basement membrane and 
some were hyalinized. The upper panels show control 
tissue from a healthy C57BL/6J mouse. 
 
A hallmark of tumors and telomere-dysfunction derived 
tumors is genome instability, resulting from 
chromosomal breakage fusion cycles. To analyze the T-
cell lymphomas for fused chromosomes as indicators of 
genome instability we screened pathological samples 
for fused chromosomes, visible as anaphase bridges. 
Spleen and liver samples readily displayed anaphases 
where the sets of daughter chromosomes were 
connected by DNA bridges, suggesting that breakage 
fusions cycles occur, and the genome in the tumors is 
unstable  (Figure 3B). 
 
 
Figure  2.  Generation  of  primary  recipient  mice  by
lentiviral  transduction of  transgenic  TRF2  into GFP  and
CD45.1 donor bone marrow. (A) A primary #1 mouse colony
(Set 1) was  generated by  the  transduction of GFP donor bone
marrow (BM) with the mTRF2 transgene and CD45.1 donor bone
marrow  with  the  GFP‐mTRF2  transgene.  For  the  primary  #2
colony  (Set  2)  only  CD45.1  donor  bone marrow was  used  and
transduced  with  a  GFP‐control,  the  mTRF2  or  the  GFP‐mTRF2
transgene.  Recipient  mice  were  C57BL/6J.  (B)  Genotyping  of
primary  recipient mice  transduced with  transgenic GFP‐mTRF2
and  GFP  by  nested  PCR  and  subsequent  Southern  analysis.
Examples for Set 1 and Set 2 are displayed. As a negative control
(‐) genomic DNA from a C57BL/6J mouse was used. As a positive
PCR  control  (+)  genomic  DNA  of  GFP‐mTRF2  expressing  HeLa
cells was included. (C) Transgenic GFP‐mTRF2 is expressed in the
hematopoietic  system  of  recipient  C57BL/6J  mice.  Indirect
immunofluorescence of bone marrow (top) and spleen (bottom)
isolated  from  a  secondary  recipient  of  GFP‐mTRF2  expressing
bone marrow. GFP‐mTRF2 was visualized by  the GFP‐tag, TRF1




Analysis of the thymomas by flow cytometry with the 
markers CD4 and CD8 suggested the presence of a 
donor derived CD4/CD8+/+ T cell lymphoma. 
However, even when the donor cells were derived from 
mice that had been transduced with GFP-mTRF2 
expressing bone marrow, less than 1% of total 
thymocytes were positive for GFP (data not shown). 
These experiments raised the possibility that the 
observed CD4/CD8+/+ T cell lymphomas originated 
from the CD45.1 donor population expressing the GFP-
mTRF2 transgene, but at the time of analysis most 
tumor cells did not overexpress mTRF2 anymore, 
raising the possibility that TRF2 overexpression is a 
cancer initiating, but not a cancer maintaining event. 
 
TRF2 has been proposed to directly interact and 
suppress ATM activation. The underlying hypothesis of 
this study was to test whether TRF2 dependent ATM 
suppression can lead to tumorigenesis. Therefore we 
tested whether ATM auto-phosphorylation was 
compromised in the tumors resulting from TRF2 
expression in the hematopoietic system. Splenocytes 
from GFP control mice, as well as cells from enlarged 
spleens in GFP-mTRF2 expressing mice  were  isolated,  
  










































cultivated, and subjected to ionizing irradiation. Then 
ATM activation was tested by immunofluorescence 
with antibodies specific for the ATM-S1981 
autophosphorylation event. No difference in ATM 
autophosphorylation could be observed between the 
samples, suggesting that ATM activation is not 
compromised in tumors resulting from overexpression 
of TRF2 in hematopoietic precursors (Figure 4A). 
 
Finally we investigated by western analysis whether 
TRF2 was still overexpressed in the tumors, and we 
tested GFP-mTRF2 expression in splenocytes isolated 
from a mouse affected by a T cell lymphoma. No band 

















































antibody (Figure 4B, upper panel) that readily 
recognizes the GFP-mTRF2 fusion expressed in HeLa 
1.2.11 cells (upper panel, right lane). However, 
endogenous TRF2 levels, normalized to the g-tubulin 
loading control, were equal. Our data therefore suggest 
that mTRF2 is not overexpressed anymore in the 
lymphomas observed in recipient mice. 
 
In summary, moderate overexpression of TRF2 in 
hematopoietic precursors in mice leads to an increase of 
tumor incident in affected animals. Tumors were 
characterized as CD4/CD8+/+ T cell lymphomas, and 
they exhibited anaphase bridges, strongly suggesting the 
possibility of  genome instability.  The modest  increase  
  



















































in cancer formation is contrary to the strong increase in 
tumor numbers observed upon overexpression of TRF2 
in basal and stem cells of the epidermis [31, 32], which 
led to XPF dependent increased skin cancer levels in the  
animals [31], suggesting a less severe impact of 
increased TRF2 levels in the hematopietic system than 
in the epidermis. Furthermore, we observed that the 
tumors resulting from transduction with TRF2 
overexpressing cells do not exhibit TRF2 over-
expression in most of their cells, raising the possibility 
that increased TRF2 expression is a driving event for 
cancer formation, but not required for tumor 
maintenance. 
 
MATERIALS AND METHODS 
 
Constructs and virus production. Lentiviral constructs 
were generated using standard cloning procedures. The 
viral backbones p156RRLsinPPTCAG-EGFP-PRE and 
p156RRLsinPPTmCMV-GFP-PRE [35] were kindly 
provided by the Verma laboratory. 
 
Lentivirus production. 293T cells were plated on one 15 
cm plate and grown in 1x DMEM supplemented with 
10% (v/v) FBS, non-essential amino acids (0.1 mM), 
Penicillin (100 units/ml) and Streptomycin (0.1 mg/ml) 
and grown to confluence. Cells were trypsinized and 
split into twelve 15 cm plates coated with poly-L-lysine 
(Sigma). When cells reached about 70% confluence 95 
μg of pVSVG, 68 μg of pREV, 176 μg pMDL, and 270 
μg transgene containing lentiviral vector were mixed. 
Under swirling CaCl2 solution was added to a final 
concentration of 0.25 M. Subsequently an equal volume 
of 2x BBS solution to the calcium-DNA mixture was 
added. The mixture was incubated for 10 minutes at 
room temperature, added drop wise at a volume of 2.25 
ml per 15 cm plate and cells were incubated at 3% CO2 
at 37oC. The medium was exchanged 12 to 16 hours 
post transfection and virus-containing media was 
harvested at 24 h intervals twice, beginning 24 hours 
after changing the medium. Every sample was 
immediately filtered through a 0.22 μm cellulose acetate 
filter and stored at 4oC. The collected medium was 
loaded into ultracentrifuge tubes and spun in a SW28 
rotor for 2 hours at 19400 rpm in a L8-80M 
ultracentrifuge (Beckman). The supernatant was poured 
off and remaining medium drops were aspirated from 
the tubes. The pellet was resuspended in 1 ml HBSS, all 
pellets from two collections were pooled and loaded on 
top of 1.5 ml of phosphate-buffered 20% (w/v) sucrose 
in small ultracentrifuge tubes. Tubes were then spun in 
the SW55 rotor for 2 hours at 21000 rpm in a L8-80M 
ultracentrifuge (Beckman). Supernatant was removed 
and pellet resuspended in 200 μl in HBSS. The virus 
suspension was vortexed for 1 to 2 hours at low speed at 
room temperature, quick-spun in microcentrifuge for 2 
seconds, the supernatant aliquoted in 20 μl aliquots and 
stored at -80oC. Virus titer was determined by the p24 
Figure  4.  The ATM  dependent  damage  response  is  not
compromised in tumor samples. (A) Immunofluorescence of
ATM autophosphorylation after  ionizing irradiation. Splenocytes




The  left panels  represent  cells  from a  control animal,  the  right
panel  from  an  animal  expressing  the  GFP‐mTRF2  fusion.  The
upper panels are before,  the  lower panels after  irradiation.  (B)
Western  analysis of  spleen  from  a  secondary  recipient mouse,
which expressed GFP‐mTRF2 and died from a CD4/CD8+/+ T cell
lymphoma.  Protein  samples  were  probed  with  antibodies
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ELISA kit (PerkinElmer) according to the manufac-
turer. 
 
Mouse strains. B6.SJL-Ptprca Pep3b/BoyJ mice (The 
Jackson Laboratory) were used to isolate bone marrow 
positive for CD45.1, TgN(beta-act-EGFP) mice [36] (a 
gift from the Verma lab, The Salk Institute) were used 
to isolate GFP-positive donor bone marrow. As 
recipient mice, C57BL/6J (The Jackson Laboratory) 
were chosen. 
 
Isolation of bone marrow. For the generation of the “Set 
1” cohort bone marrow was isolated from 15 male 
B6.SJL-Ptprca Pep3b/BoyJ mice (CD45.1 donor, The 
Jackson Laboratory) and 5 male TgN(beta-act-EGFP) 
mice (GFP donor, a gift from the Verma lab, The Salk 
Institute). For the generation of the “Set 2” population 
done bone marrow was isolated from 20 male B6.SJL-
Ptprca Pep3b/BoyJ animals (CD45.1 donor, The Jackson 
Laboratory). The mice were sacrificed by cerebral 
dislocation and femur and tibia were placed into 1x 
PBS/2 % (v/v) BIT9500 (StemCell Technologies). To 
isolate the bone marrow, femur and tibia were mortared, 
the suspension filtered through a Cell Strainer (BD 
Falcon) and centrifuged for 10 minutes at 700 x g. The 
pellet was resuspended in 1x PBS and cell numbers 
were determined by counting a 1:20 dilution of the 
suspension using a Coulter Counter. Suspensions were 
diluted to 5x107 cells/ml. To enrich hematopoietic stem 
cells, cell suspensions were separated using the 
StemStepTM cell separation system (StemCell Tech-
nologies) as directed. The cell numbers of the enriched 
hematopoietic stem cells were determined and 
resuspended in Myelocult M5300 (StemCell Tech-
nologies). 
 
Infection of bone marrow. Sorted bone marrow cells 
were diluted to approximately 1.2x107 to 1.4x107 
cells/ml in Myelocult M5300 medium and 200 ml virus 
was added to the cells. The suspension was incubated at 
37oC o/n and then the suspension was washed once with 
1x HBSS, centrifuged for 5 minutes at 400 x g, and 
resuspended in 1x HBSS. 
 
Transplantation of bone marrow. Prior to transplant-
tation recipient C57BL/6J mice were irradiated with 
11Gy and subsequently deeply anesthetized. Each 
mouse received lateral tail vein injections of 100.000 to 
200.000 cells diluted in 300 ml 1x HBSS. During the 
first two weeks post transplantation all mice were 
maintained on Baytril water (Bayer Health Care). All 
mice were stored in the Biohazard suite at the Salk 
Institute’s Animal Facility throughout the course of the 
experiment. 
 
Genotyping of primary and secondary recipient mice. 
Genomic DNA from blood and tissue samples of 
C57BL/6J mice as well as HeLa 1.2.11 expressing GFP-
mTRF2 cells was isolated using the DNeasy tissue kit 
(Qiagen). Nested PCR was performed with the outer 
primer pair (mTRF2 Outer F1: 5’-GCA GAT TGC TGT 
TGG AGG AGG-3’; WPRE R1: 5’-GCC ACA ACT 
CCT CAT AAA GAG ACA G-3’) generating a 626 bp 
PCR-product, followed by PCR with the inner pair 
(mTRF2 Inner F1: 5’-ATG TCA GCA TCC AAG CCC 
AGA G-3’; mTRF2 Inner R1: 5’-CCA GTT TCC TTC 
CCC GTA TTT G-3’) generating a 252 bp PCR-
product. Integration of the transgene into the hemato-
poietic system of primary recipient mice was verified by 
nested PCR and the PCR-product was separated on a 
1.3% (w/v) Agarose gel. The gel was blotted onto a 
Hybond-N+ nitrocellulose membrane, (Amersham) 
following standard Southern analysis procedures, using 
the mTRF2 cDNA as probe. 
 
Protein isolation. Primary cells were washed with 1x 
PBS on the plate and trypsinized using 2.5% (v/v) 
Trypsin/EDTA. Cell numbers were determined with a 
Coulter Counter. Cells were spun for 5 minutes at 1000 
rpm and washed twice in 1x PBS and the cell pellet was 
resuspended at a dilution of 10000 cells/ml in 4x 
NuPAGE LDS sample buffer (Invitrogen). 
 
Tissue samples were mashed through a 70 mm Cell 
Strainer (BD Falcon) with the rubber end of a syringe in 
the presence of 1x PBS/2% (v/v) FCS. Cell numbers 
were determined with a Coulter Counter.  The cell 
suspension was then spun for 5 minutes at 1000 rpm 
and washed twice in 1x PBS. The cell pellet was 
resuspended at a dilution of 10000 cells/μl in 4x 
NuPAGE LDS sample buffer (Invitrogen). 
 
Western blotting. Whole cell extracts of primary cells or 
protein extracts isolated from tissue samples in 4x 
NuPAGE LDS sample buffer were separated on 3-8% 
(w/v) Tris-Acetat gradient gels (Invitrogen) and 
transferred to nitrocellulose. Blocking and incubation 
with primary and secondary antibodies was performed in 
5% (w/v) milk and 0.1% (v/v) Tween in 1x PBS. 
Antibodies: rabbit-anti-mTRF2 #6889 (1/1000, Karlseder 
lab), mouse-anti-g-Tubulin GTU-88 (1/10000, Sigma), 
mouse-anti-GFP (1/200, Chemicon International). After 
incubation with secondary antibodies (1/5000, 
Amersham), all blots were developed using the ECL kit 
(Amersham). 
 
Immunofluorescence on cultured cells, bone marrow and 
spleen. Immunofluorescence on cultured cells was per-
formed as described  [21, 37].  Bone marrow  and  spleen 
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suspension from C57BL/6J mice were attached to 
microscope slides by loading 200 μl of cell suspension 
into cytofunnels (Thermo Electron Corporation) and 
centrifugation in a Shandon Cytospin 4 Cytocentrifuge 
(Thermo Scientific) for 10 minutes at 800 rpm. Primary 
antibodies: rabbit-anti-mTRF1 #6888 (1/500, Karlseder 
lab), rabbit-anti-mTRF2 #6889 (1/500, Karlseder lab), 
mouse-anti-TRF2 (1/500, upstate biotechnology). 
Secondary antibodies: donkey-anti-rabbit-FITC (1/200, 
Jackson), donkey-anti-mouse-FITC (1/200, Jackson), 
donkey-anti-rabbit-TRITC (1/200, Jackson). Pictures 
were taken on an Axioplan2 Zeiss microscope with a 
Hamamatsu digital camera supported by OpenLab 
software. 
 
Immunofluorescence on microtome sections. Tissue 
sections of mice were isolated and fixed in phosphate-
buffered 4% (v/v) formaldehyde and transferred to 
phosphate-buffered 30% (w/v) sucrose after one day. 
Sections were blocked with 3% (v/v) FCS in TBS with 
0.25% (v/v) Triton-X 100 for 1 hour and incubated o/n 
at 4oC. Primary antibody: rabbit-anti-ATM pS1981 
(1/500, Rockland). Then the sections were rinsed in 3% 
(v/v) FCS in TBS with 0.25% (v/v) Triton-X 100. The 
sections were incubated with the second antibody in 3% 
(v/v) FCS in TBS with 0.25% (v/v) Triton-X 100 for 1 
to 2 hours, followed by three washing steps in TBS. 
Secondary antibody: goat-anti-rabbit-TRITC (1/200, 
Jackson). To stain DNA the sections were incubated in 
a 1/30000 dilution of 4’, 6’-diamidino-2-phenylindole 
(DAPI) in TBS for 5 minutes. Sections were mounted 
on coverslip using Dabco/PVA, dried over night at 4 oC 
in the dark, and sealed with nail polish. Pictures were 
taken on a Leica TCS SP2 AOBS and analyzed by LCS 
Lite software. 
 
Flow cytometry. Aliquots of bone marrow cells and 
thymocytes were stained with anti-mouse CD45.1 
antibody (A20) conjugated to R-Phycoerythrin (R-PE) 
to detect CD45.1 donor bone marrow. If mice were 
transplanted with GFP-donor bone marrow, the 
presence of the GFP signal was used to evaluate the 
presence of donor bone marrow. Lineage analysis was 
performed by double staining using anti-mouse CD45.1 
R-PE antibody with each of the following antibodies: 
CD4 (RM4-5.B) and CD8 (53-6.7). Primary antibodies 
were purchased from BD Biosciences, the secondary 
antibody was purchased from Molecular Probes. Flow 
cytometric analysis was performed on a LSR I 3-laser 
6-color analytical flow cytometer (Becton-Dickinson) 
and data were analyzed using the CellQuest software 
(Becton-Dickinson). 
 
Pathology. Tissue samples of mice were fixed in 4% 
(v/v) p-formaldehyde, transferred to phosphate-buffered 
30% (w/v) sucrose and stored at 4oC in the dark. 
Pathological studies were carried out at the Department 
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